| Name | Title | Contact Details |
|---|
Altru Health System is a community-owned, integrated system with an acute care hospital, a specialty hospital, more than a dozen clinics in Grand Forks and the region, a large home care network, and a congregate living facility. It employs more than 200 physicians and 4,000 staff and has an annual net operating revenue of more than $450 million. As the first member of the Mayo Clinic Care Network, Altru’s providers have access to clinically integrated tools extending Mayo Clinic’s knowledge and expertise to patients.
Fisher-Titus Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Fisher-Titus Medical Center is based in Norwalk, OH. You can find more information on Fisher-Titus Medical Center at www.ftmc.com
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART LinkerSM platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates.
Our revolutionary technology is radically different than any other form of automated medical billing software or revenue cycle management. Unlike a PMS vendor or a clearinghouse, the Encoda BackOffice suite of products enhances and improves existing billing systems and billing service providers’ operations, making them more intelligent. The difference? On average, our customers increase staff productivity by more than 30% and dramatically reduce operating expenses, helping their practices to grow. How do we do this? We apply business intelligence and programming logic tools from the high-tech community to healthcare, and pass those technological advantages on to medical business offices. In adding this advanced technology to our clients’ systems, we create a direct connection between clients and payers, seamlessly integrating the two environments eliminating the need for human intervention.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.